Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
Anaplastic thyroid carcinoma (ATC) is a deadly disease with very limited therapeutic options. There is an urgent need for new and efficacious drugs. Unfortunately accrual in clinical trials is problematic because of the rarity of the disease and often poor performance status at diagnosis. Recently s...
Saved in:
| Main Authors: | Valérie Spalart, Barbara Legius, Kurt Segers, Johan Coolen, Brigitte Maes, Lynn Decoster |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2019/9095753 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel approach to regulate glucose uptake in an anaplastic thyroid cancer cell line
by: Shabnam Heydarzadeh, et al.
Published: (2025-01-01) -
Targeted therapy of anaplastic thyroid cancer
by: P. A. Nikiforovich, et al.
Published: (2023-03-01) -
Risk Factors for Anaplastic Thyroid Cancer
by: V. Zivaljevic, et al.
Published: (2014-01-01) -
Anaplastic thyroid cancer: current state of the problem
by: P. A. Nikiforovich, et al.
Published: (2025-05-01) -
Anaplastic thyroid cancer: current capabilities of an oncologist
by: A. L. Pylev, et al.
Published: (2023-06-01)